DB05404InvestigationalSmall molecule
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
- Mechanism
- Curator reviewed
AZD3355 is reflux inhibitors which offer a new approach to the treatment of Gastroesophageal reflux disease (GERD) by improving the function of the lower oesophageal sphincter (LOS) through receptors responsible for opening and closing the sphincter.
- Primary indication
- Investigated for use/treatment in gastroesophageal reflux disease (GERD).Curator reviewed
- Code names
- AZD 3355
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with AZD 3355, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account